Medical - Diagnostics & Research
Compare Stocks
4 / 10Stock Comparison
OPK vs DBVT vs PRGO vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Drug Manufacturers - Specialty & Generic
Medical - Diagnostics & Research
OPK vs DBVT vs PRGO vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology | Drug Manufacturers - Specialty & Generic | Medical - Diagnostics & Research |
| Market Cap | $846M | $1712.35T | $1.61B | $30.32B |
| Revenue (TTM) | $581M | $0.00 | $4.18B | $16.63B |
| Net Income (TTM) | $-213M | $-168M | $-1.82B | $1.39B |
| Gross Margin | 47.7% | — | 34.2% | 26.1% |
| Operating Margin | -17.4% | — | -4.1% | 13.9% |
| Forward P/E | — | — | 5.6x | 14.1x |
| Total Debt | $434M | $22M | $3.97B | $16.17B |
| Cash & Equiv. | $369M | $194M | $532M | $1.98B |
OPK vs DBVT vs PRGO vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| OPKO Health, Inc. (OPK) | 100 | 49.1 | -50.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| IQVIA Holdings Inc. (IQV) | 100 | 119.5 | +19.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OPK vs DBVT vs PRGO vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OPK is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.25, Low D/E 34.2%, current ratio 3.97x
- Beta 1.25, current ratio 3.97x
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs PRGO's -51.2%
PRGO carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower P/E (5.6x vs 14.1x)
- Beta 1.18 vs IQV's 1.33, lower leverage
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
IQV is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
- 166.5% 10Y total return vs PRGO's -77.7%
- 5.9% revenue growth vs DBVT's -100.0%
- 8.3% margin vs PRGO's -43.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 5.9% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.6x vs 14.1x) | |
| Quality / Margins | 8.3% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 1.18 vs IQV's 1.33, lower leverage | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs PRGO's -51.2% | |
| Efficiency (ROA) | 4.7% ROA vs DBVT's -89.0% |
OPK vs DBVT vs PRGO vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
OPK vs DBVT vs PRGO vs IQV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IQV leads in 2 of 6 categories
PRGO leads 2 • DBVT leads 1 • OPK leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IQV leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV and DBVT operate at a comparable scale, with $16.6B and $0 in trailing revenue. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, IQV holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $581M | $0 | $4.2B | $16.6B |
| EBITDAEarnings before interest/tax | -$33M | -$112M | $58M | $3.5B |
| Net IncomeAfter-tax profit | -$213M | -$168M | -$1.8B | $1.4B |
| Free Cash FlowCash after capex | -$174M | -$151M | $108M | $2.7B |
| Gross MarginGross profit ÷ Revenue | +47.7% | — | +34.2% | +26.1% |
| Operating MarginEBIT ÷ Revenue | -17.4% | — | -4.1% | +13.9% |
| Net MarginNet income ÷ Revenue | -36.6% | — | -43.5% | +8.3% |
| FCF MarginFCF ÷ Revenue | -30.0% | — | +2.6% | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -17.2% | — | -7.2% | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +30.0% | +91.5% | -56.4% | +15.0% |
Valuation Metrics
PRGO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than IQV's 13.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $846M | $1712.35T | $1.6B | $30.3B |
| Enterprise ValueMkt cap + debt − cash | $910M | $1712.35T | $5.1B | $44.5B |
| Trailing P/EPrice ÷ TTM EPS | -3.73x | -0.76x | -1.14x | 22.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 5.56x | 14.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | — | 7.42x | 12.97x |
| Price / SalesMarket cap ÷ Revenue | 1.39x | — | 0.38x | 1.86x |
| Price / BookPrice ÷ Book value/share | 0.68x | 0.66x | 0.55x | 4.67x |
| Price / FCFMarket cap ÷ FCF | — | — | 11.12x | 14.78x |
Profitability & Efficiency
IQV leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs OPK's 3/9, reflecting mixed financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -16.8% | -130.2% | -50.7% | +22.1% |
| ROA (TTM)Return on assets | -11.0% | -89.0% | -19.8% | +4.7% |
| ROICReturn on invested capital | -11.9% | — | +3.7% | +8.7% |
| ROCEReturn on capital employed | -11.5% | -145.7% | +4.3% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.34x | 0.13x | 1.35x | 2.44x |
| Net DebtTotal debt minus cash | $65M | -$172M | $3.4B | $14.2B |
| Cash & Equiv.Liquid assets | $369M | $194M | $532M | $2.0B |
| Total DebtShort + long-term debt | $434M | $22M | $4.0B | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | -1.10x | -189.82x | -7.20x | 3.10x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IQV five years ago would be worth $7,621 today (with dividends reinvested), compared to $2,947 for OPK. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +4.9% | -13.5% | -20.7% |
| 1-Year ReturnPast 12 months | -10.4% | +110.4% | -51.2% | +16.5% |
| 3-Year ReturnCumulative with dividends | -39.8% | +19.7% | -58.1% | -5.9% |
| 5-Year ReturnCumulative with dividends | -70.5% | -69.1% | -60.1% | -23.8% |
| 10-Year ReturnCumulative with dividends | -89.1% | -87.0% | -77.7% | +166.5% |
| CAGR (3Y)Annualised 3-year return | -15.6% | +6.2% | -25.2% | -2.0% |
Risk & Volatility
Evenly matched — DBVT and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 1.26x | 1.18x | 1.33x |
| 52-Week HighHighest price in past year | $1.60 | $26.18 | $28.44 | $247.05 |
| 52-Week LowLowest price in past year | $0.98 | $7.53 | $9.23 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +70.0% | +76.3% | +41.2% | +72.3% |
| RSI (14)Momentum oscillator 0–100 | 41.8 | 48.1 | 60.9 | 58.5 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 252K | 3.4M | 1.6M |
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: OPK as "Buy", DBVT as "Buy", PRGO as "Hold", IQV as "Buy". Consensus price targets imply 156.2% upside for OPK (target: $3) vs 26.3% for IQV (target: $226). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $2.87 | $46.33 | $20.00 | $225.63 |
| # AnalystsCovering analysts | 13 | 15 | 36 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 10 | 2 |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.6% | 0.0% | 0.0% | +4.1% |
IQV leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
OPK vs DBVT vs PRGO vs IQV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OPK or DBVT or PRGO or IQV a better buy right now?
For growth investors, IQVIA Holdings Inc.
(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OPK or DBVT or PRGO or IQV?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — OPK or DBVT or PRGO or IQV?
Over the past 5 years, IQVIA Holdings Inc.
(IQV) delivered a total return of -23. 8%, compared to -70. 5% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: IQV returned +166. 5% versus OPK's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OPK or DBVT or PRGO or IQV?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 13% more volatile than PRGO relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — OPK or DBVT or PRGO or IQV?
By revenue growth (latest reported year), IQVIA Holdings Inc.
(IQV) is pulling ahead at 5. 9% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OPK or DBVT or PRGO or IQV?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -36. 1% for OPK. At the gross margin level — before operating expenses — PRGO leads at 35. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OPK or DBVT or PRGO or IQV more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 14. 1x for IQVIA Holdings Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPK: 156. 2% to $2. 87.
08Which pays a better dividend — OPK or DBVT or PRGO or IQV?
In this comparison, PRGO (9.
8% yield) pays a dividend. OPK, DBVT, IQV do not pay a meaningful dividend and should not be held primarily for income.
09Is OPK or DBVT or PRGO or IQV better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OPK and DBVT and PRGO and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OPK is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; IQV is a mid-cap quality compounder stock. PRGO pays a dividend while OPK, DBVT, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.